Helius Medical: A Failed Clinical Trial, Redacted Data, And...
Helius Medical is a reverse-merger, single-product, pre-revenue medical device company with a unique device that delivers stimulation to the tongue...
Research
(If you're unable to access an article, contact us and we'll email you the full article)
Orchids Paper: Toliet Paper Never Looked So Dirty –...
Each 2018 quarter, Orchids Paper (TIS) has had a consecutively worse financial performance. For the past two quarters, Orchids' gross...
Transenterix: Surgical Robot Experts Call Its Senhance System ‘A...
TransEnterix (TRXC) was originally funded by a notorious investor recently charged by the SEC for orchestrating pump and dumps. A...
Namaste Technologies’ Major Related-Party Transactions Go Beyond Citron’s Findings
We found Namaste’s consultants are actually officers of the company, including the head of its audit committee. While other companies...
Generation Next Franchise Brands Is A House Made Of...
Generation Next Franchise Brands Is A House Made Of Frozen Yogurt That’s About To Melt Generation Next Franchise Brands’ (VEND)...
Viveve Medical Is A Sinking Ship, $0.90 Price Target
Viveve Medical (VIVE) had a horrendous Q1 2018 report with a big revenue miss, decreased gross margins, and a $12M...
Level Brands Is A Low Value Reg A+ IPO...
Level Brands (LEVB) is among the latest 2017 Reg A+ IPOs – so far they are all trading below their...
We Believe Capstone Turbine Is Going To Give Back...
Capstone Turbine has gone up over 100% in the past 3 months, but business is not doing well as they...
Longfin’s Acquisition Of Ziddu.com Added Over $2B To Its...
Longfin had a Reg A+ IPO on December 13, 2017, originally at a $382.5M market cap which ballooned to its...
The Clock Is Ticking For Nymox Pharma’s European Drug...
Nymox drug, fexapotide, to treat enlarged prostate, is about to have its marketing application decided in Europe within a few...
10 Reasons Why We Remain Confidently Short Ampio Pharmaceuticals
Although we started shorting Ampio (AMPE) in the high $3s, we continue to hold our short position. We don’t believe...
ClearSign Combustion’s Duplex Technology Is A Commercial Failure; The...
ClearSign Combustion’s Duplex Technology Is A Commercial Failure, The Stock’s Downtrend Will Continue ClearSign’s green energy Duplex technology has been...
Track Record
We have an over 90% success rate
3rd Party Verified:
(click on the stock symbols below to see the reports)
Get Our Latest Reports Delivered To Your Inbox (we will not share your email with anyone)